Fig. 1 | Nature Communications

Fig. 1

From: LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling

Fig. 1

The lncRNA-p21 level is increased in NEPC cells. a The qPCR analysis to detect 75 lncRNAs expressed in NEPC-PDX and adenocarcinoma-PDX samples. b Detecting lncRNAs expressions in LNCaP and NE1.8 cells by qPCR analysis. c The qPCR analysis of lncRNA-p21 expression in CWR22RV1 (22RV1), C4-2, DU145, NCI-H660, and PC3 cells. d The qPCR analysis of lncRNA-p21 expression in C4-2 and 22RV1 cells after Enz treatment. e Detecting the lncRNA-p21 expression in Enz-treated C4-2 cells by RNA in situ hybridization (Scale bar = 2 μm). f The lncRNA-p21 expression in human normal prostate tissues (n = 10) and human PCa tissues (n = 34). g The lncRNA-p21 expression in PCa tissues before and after ADT (n = 7). h Detection of lncRNA-p21 level in human CRPC (n = 10) and PCa small cell carcinoma (SCC) (n = 10) samples. For B and D, data are presented as mean ± SD, **p < 0.005, by t-test

Back to article page